Plastic article or earthenware shaping or treating: apparatus – Dough divider type including trap chamber – Including positive discharge assistant in supply hopper
Reexamination Certificate
2007-08-28
2007-08-28
Campell, Bruce R. (Department: 1648)
Plastic article or earthenware shaping or treating: apparatus
Dough divider type including trap chamber
Including positive discharge assistant in supply hopper
C435S069100, C435S320100
Reexamination Certificate
active
10851688
ABSTRACT:
Methods for separating AAV empty capsids from mixtures of AAV vector particles and AAV empty capsids are described. The methods use column chromatography techniques and provide for commercially viable levels of recombinant AAV virions.
REFERENCES:
patent: 6593123 (2003-07-01), Wright et al.
patent: WO97/08298 (1997-03-01), None
patent: WO99/11764 (1999-03-01), None
patent: WO 02/12455 (2002-02-01), None
patent: WO 03/046142 (2003-06-01), None
Gao, G., G. Qu, et al., Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo., Human Gene Therapy, Oct. 10, 2000, 2079-91, vol. 11.
Snyder, R. O. and T. R. Flotte, Production of clinical-grade recombinant adeno-associated virus vectors., Current Opinion in Biotechnology, 2002, 418-23, vol. 13.
Summerford, C. and R. J. Samulski, Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions., Journal of Virology, Feb. 1998, 1438-45, vol. 72.
Clark, K. R., X. Liu, et al., Highly purified recombinant adeno-associated virus vectors are biologially active and free of detectable helper and wild-type viruses., Human Gene Therapy, Apr. 10, 1999, 1031-9. vol. 10.
Brument, N., R. Morenweiser, et al., A versatile and scalable two-step ion-exchange chromatography process for the purification of recombinant adeno-associated virus serotypes-2 and -5., Molecular Therapy, Nov. 2002, 678-86, vol. 6, No. 5.
Kaludov, N., B. Handelman, et al., Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography., Human Gene Therapy, Jul. 1, 2000, 1235-43, vol. 13.
Zolotukhin, S., M. Potter, et al., Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors, Methods, Jul. 15, 2002, 158-67, vol. 28.
Potter, M., K. Chesnut, et al., Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors., Methods in Enzymology, 2002, 413-430, vol. 346.
Parker A., Nagy D., Vargas J., Anand V., Qu G., Sommer J., Wright F., Couto L., In vivo performance of AAV-2 vectors purified by CsCl gradient centrifugation or column chromatography., Molecular Therapy, 2003, S390 vol. 7.
Wright, J. F., T. Le, et al., Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and forumulation., Molecular Therapy, Jul. 2005, 171-8, vol. 12, No. 1.
Sommer, JM., P. H. Smith, et al., Quantification of adeno-associated virus particles and empty capsids by optical density measurement., Molecular Therapy, Jan. 2003, 122-8, vol. 7, No. 1.
Grimm, D., A. Kern, et al., Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2., Gene Therapy, 1999, 1322-30, vol. 6.
Qu G., et al., Characterization of AAV Vectors Expressing Human Coagulation Factor IX Produced at Intermediate Scale., Molecular Therapy, May 2002, S50, vol. 5.
Lewis, U. J., E. V. Cheever, et al., Kinetic study of the deamidation of growth hormone and prolactin., Biochimica et Biophysica Acta, 1970, 498-508, vol. 214.
Davidoff, A. M., C. Y. NG, et al., Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock., Journal of Virological Methods, 2004, 209-15, 121.
Wu, Xaiobing, et al., A novel method for purification of recombinant adeno-associated virus vectors on a large scale., Chinese Science Bulletin, 2001, 485-489, vol. 46.
Anderson, et al., A Method for the Preparation of Highly Purified Adeno—Associated Virus Using Affinity Column Chromatography, Protease Digestion and Solvent Extraction,Journal of Viralogical Methods 85:23-34 (2000).
Vellekamp, et al., “Empty Capsids in Column-Purified Recombinant Adenovirus Preparations,”Human Gene Therapy 12:1923-1936 (2001).
Zoluthkin, et al., “Recombinant Adeno-Associated Virus Purification Using Novel Methods Improves Infectious Titer and Yield,”Gene Therapy 6:973-985 (1999).
Kaludov et al., “Scalable Purification of Adeno-Associated Virus Type 2, 4, or 5 Using Ion-Exchange Chromatography,” Human Gene Therapy, 13:1235-1243 (2002).
Qu et al., “Scaling-Up Production of Recombinant AAV Vectors for Clinical Applications,” Current Opinion in Drug Discovery & Development, 3(6):750-755 (2000).
Debelak, et al, “Cation-Exchange High-Performance Liquid Chromatography of Recombinant Adeno-Associated Virus Type 2,” J. Chromat.B, 740:195-202 (2000).
Qu Guang
Wright John Fraser
Campell Bruce R.
Genzyme Corporation
Li Bao Qun
Robins & Pasternak LLP
LandOfFree
Methods for producing preparations of recombinant AAV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for producing preparations of recombinant AAV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for producing preparations of recombinant AAV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3878004